Literature DB >> 12476793

Mechanisms of interferon mediated anti-viral resistance.

C J Clarke1, J A Trapani, R W Johnstone.   

Abstract

Interferons (IFNs) are an important part of immune responses and are believed to protect the host from viral and bacterial pathogens as well as having a role in rejection of malignancies. The well-known anti-viral and cytostatic properties of IFNs have led to the clinical use of these proteins to treat some cancers and viral infections. Extensive research has begun to unravel much of the molecular basis for the biological effects of IFNs, and this information could now be used as a foundation for the development of novel therapeutic strategies that avoid some of the acknowledged shortcomings of cytokine therapies. This review explains the current model of IFN action, during viral infections and the potential for well-established and emerging groups of IFN inducible genes as therapeutic targets is highlighted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12476793

Source DB:  PubMed          Journal:  Curr Drug Targets Immune Endocr Metabol Disord        ISSN: 1568-0088


  11 in total

Review 1.  Innovative techniques and applications in histochemistry and cell biology.

Authors:  Esther Asan
Journal:  Histochem Cell Biol       Date:  2003-11-28       Impact factor: 4.304

2.  Expression of IFI 16 in epithelial cells and lymphoid tissues.

Authors:  Wu Wei; Christopher J P Clarke; Gino R Somers; Kim S Cresswell; Kate A Loveland; Joseph A Trapani; Ricky W Johnstone
Journal:  Histochem Cell Biol       Date:  2002-12-20       Impact factor: 4.304

3.  Rapid upregulation of interferon-regulated and chemokine mRNAs upon injection of 108 international units, but not lower doses, of adenoviral vectors into the brain.

Authors:  Jeffrey M Zirger; Carlos Barcia; Chunyan Liu; Mariana Puntel; Ngan Mitchell; Iain Campbell; Maria Castro; Pedro R Lowenstein
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Type I interferon limits the capacity of bluetongue virus to infect hematopoietic precursors and dendritic cells in vitro and in vivo.

Authors:  Teresa Rodríguez-Calvo; José-Manuel Rojas; Verónica Martín; Noemí Sevilla
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

5.  miR-28-3p is a cellular restriction factor that inhibits human T cell leukemia virus, type 1 (HTLV-1) replication and virus infection.

Authors:  Xue Tao Bai; Christophe Nicot
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

6.  Pharmacologic activation of the innate immune system to prevent respiratory viral infections.

Authors:  Guanjun Cheng; Liang-Chuan S Wang; Zvi G Fridlender; Guang-Shing Cheng; Bei Chen; Nilam S Mangalmurti; Vassiliki Saloura; Zaifang Yu; Veena Kapoor; Krystyna Mozdzanowska; Edmund Moon; Jing Sun; James L Kreindler; Noam A Cohen; Andrew J Caton; Jan Erikson; Steven M Albelda
Journal:  Am J Respir Cell Mol Biol       Date:  2010-12-10       Impact factor: 6.914

7.  Refractoriness of interferon-beta signaling through NOD1 pathway in mouse respiratory epithelial cells using the anticancer xanthone compound.

Authors:  Zaifang Yu; Jarrod D Predina; Guanjun Cheng
Journal:  World J Biol Chem       Date:  2013-05-26

8.  High-throughput screening normalized to biological response: application to antiviral drug discovery.

Authors:  Dhara A Patel; Anand C Patel; William C Nolan; Guangming Huang; Arthur G Romero; Nichole Charlton; Eugene Agapov; Yong Zhang; Michael J Holtzman
Journal:  J Biomol Screen       Date:  2013-07-16

9.  Leukocyte-derived IFN-α/β and epithelial IFN-λ constitute a compartmentalized mucosal defense system that restricts enteric virus infections.

Authors:  Tanel Mahlakõiv; Pedro Hernandez; Konrad Gronke; Andreas Diefenbach; Peter Staeheli
Journal:  PLoS Pathog       Date:  2015-04-07       Impact factor: 6.823

10.  Type I interferons produced by hematopoietic cells protect mice against lethal infection by mammalian reovirus.

Authors:  Cecilia Johansson; J Denise Wetzel; Jianping He; Carmen Mikacenic; Terence S Dermody; Brian L Kelsall
Journal:  J Exp Med       Date:  2007-05-14       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.